A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial) (ADOPT PGx)
Chronic Pain
About this trial
This is an interventional treatment trial for Chronic Pain focused on measuring Pharmacogenetic, CYP2D6, CYP2C19
Eligibility Criteria
Inclusion Criteria: Chronic Pain Trial Age ≥ 18 years English speaking or Spanish speaking Seen at primary care clinics (such as, but not limited to, Internal Medicine, Family Medicine or Pediatrics) or patients seen in pain-relevant specialty clinics History of pain for at least the last 3 months Currently treated or being considered for treatment with tramadol, hydrocodone, or codeine to improve pain management Exclusion Criteria Trial-wide: Life expectancy less than 12 months Are too cognitively impaired to provide informed consent and/or complete study protocol Are institutionalized or too ill to participate (i.e. mental or nursing home facility or incarcerated) Have a history of allogeneic stem cell transplant or liver transplant People with prior clinical pharmacogenetic test results for genes relevant for the study in which they will enroll (CYP2D6 for the pain studies and CYP2D6 or CYP2C19 for depression) or already enrolled in an ADOPT PGx trial Chronic Pain Plan to move out of the area within 6 months of enrollment Undergoing treatment for an active cancer diagnosis Currently taking daily opioids other than tramadol, codeine or hydrocodone
Sites / Locations
- University of Florida - Gainesville
- University of Florida - Jacksonville
- Eskenazi Health
- Indiana University
- Icahn School of Medicine at Mount Sinai
- The Institute for Family Health
- Duke University Medical Center
- Meharry Medical College
- Nashville General Hospital
- Vanderbilt University Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Chronic Pain - Immediate PGx Testing
Chronic Pain - Delayed PGx Testing
Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider
Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period